LON:TILS Tiziana Life Sciences (TILS) Share Price, News & Analysis Add Compare Share Share Stock Analysis Stock Analysis About Tiziana Life Sciences Stock (LON:TILS) Get Tiziana Life Sciences alerts:Sign Up Key Stats Today's Range N/A50-Day Range N/A52-Week Range N/AVolume297,127 shsAverage Volume522,223 shsMarket Capitalization£113.85 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Tiziana Life Sciences Plc, a clinical stage biotechnology company, focuses on the discovery and development of molecules and related diagnostics to treat diseases in oncology and immunology in the United Kingdom. Its product pipeline includes Foralumab (TZLS-401), a human anti-CD3 monclonal antibody for the treatment of autoimmune and inflammatory diseases, such as GvHD, ulcerative colitis, Crohn's disease, multiple sclerosis, type-1 diabetes, inflammatory bowel diseases, psoriasis, and rheumatoid arthritis; and Milciclib (TZLS-201), which is an orally bioavailable, small molecule inhibitor of cyclin-dependent kinases and Src family kinases for the treatment of hepatocellular carcinoma. The company also develops anti-IL6R (TZLS-501), a human anti-interleukin-6 receptor monoclonal antibody for the treatment of IL6-induced inflammation, primarily to treat COVID-19 patients with severe respiratory symptoms. It has a collaboration agreement with FHI Clinical Inc. to conduct a phase 2 clinical trial for treating hospitalized severe COVID-19 patients with intranasal foralumab, a human anti-CD3 monoclonal antibody. The company was incorporated in 1998 and is headquartered in London, the United Kingdom. Tiziana Life Sciences Plc is a subsidiary of Planwise Group Limited. Read More Receive TILS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Tiziana Life Sciences and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. TILS Stock News HeadlinesTiziana Life Sciences Stock (TLSA) Opinions on Clinical Trial UpdatesAugust 6, 2026 | quiverquant.comQTiziana Life Sciences CEO Increases Stake with Nasdaq Share PurchaseAugust 6, 2026 | tipranks.comDo this before December or regret itPorter Stansberry believes President Trump will use the December G20 Summit in Miami to unveil a radical monetary reset tied to executive order 14241 - one he says could draw a sharp dividing line between prepared investors and those left behind. The last time America reset its money - under Nixon in the 1970s - it produced an average of 1,300 new millionaires per day for over 50 years. Stansberry's new documentary names a core group of assets he believes are positioned to surge as Trump's new dollar rolls out. Watch Porter Stansberry's full briefing and get his three steps to prepare before December.September 12 at 1:00 AM | Porter & Company (Ad)Tiziana Life Sciences CEO Makes Bold Insider Move Signaling Growing ConfidenceAugust 5, 2026 | tipranks.comTiziana Life Sciences CEO Boosts Stake as Lead MS Therapy ProgressesAugust 4, 2026 | tipranks.comTiziana Life Sciences Says Imaging Results Show Neuroinflammation Reduction in Rare Neurodegenerative ConditionJuly 31, 2026 | benzinga.comTiziana Life Sciences Posts Reproducible PET Evidence of Reduced Brain Inflammation in Third MSA PatientJuly 31, 2026 | tipranks.comTiziana Life Sciences Reports Reduced Neuroinflammation in Third Multiple System Atrophy Patient Treated with Intranasal ForalumabJuly 31, 2026 | quiverquant.comQSee More Headlines TILS Stock Analysis - Frequently Asked Questions How were Tiziana Life Sciences' earnings last quarter? Tiziana Life Sciences PLC (LON:TILS) posted its quarterly earnings data on Wednesday, September, 30th. The biotechnology company reported ($2.60) EPS for the quarter, topping analysts' consensus estimates of ($4.00) by $1.40. How do I buy shares of Tiziana Life Sciences? Shares of TILS stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock. What other stocks do shareholders of Tiziana Life Sciences own? Based on aggregate information from My MarketBeat watchlists, some other companies that Tiziana Life Sciences investors own include Tiziana Life Sciences (TLSA), Meta Platforms (META), Micron Technology (MU), ServiceNow (NOW), NVIDIA (NVDA) and Tesla (TSLA). Company Calendar Last Earnings9/30/2020Today9/11/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeLON SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolLON:TILS Previous SymbolLON:ADI CIKN/A Webwww.tizianalifesciences.com Phone+44-20-74952379FaxN/AEmployees11Year FoundedN/AProfitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity Ratio2.36 Current Ratio6.54 Quick Ratio6.41 Sales & Book Value Annual Sales-£3.60 million Price / Sales0.00 Cash FlowN/A Price / Cash Flow2.28 Book ValueGBX 23.50 per share Price / BookN/AMiscellaneous Outstanding Shares194,612,000Free FloatN/AMarket Cap£113.85 million OptionableNot Optionable BetaN/A 7 Stocks That Could Lead the Next Market BoomTesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.Get This Free Report This page (LON:TILS) was last updated on 9/12/2026 by MarketBeat.com Staff. From Our PartnersWhy I'm NOT Buying the SpaceX IPO (And What I'm Buying Instead)Don't buy Nvidia... Not when the AI companies that will define the next decade are selling for pennies. You wo...Decentralized Masters | SponsoredThe $15 Gold Fund That Pays Up to $1,152/MonthGold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying...Investors Alley | SponsoredBlackRock and Vanguard already own THISInstitutions own roughly 88 percent of an overlooked American oil and natural gas company. BlackRock holds 32 ...Monument Traders Alliance | SponsoredAfter KDA, PRE, and OCEAN—this is the one17,556% on KDA. Here's what I'm buying now. It's a coin under $1.00 that most investors have never heard of...Crypto 101 Media | SponsoredThey didn't warn anyone in 1971. This time someone is warning you.On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredGold majors have a big problemNewmont spent 15 billion dollars acquiring Newcrest in 2023, the largest deal in gold mining history. Yet prod...Golden Portfolio | SponsoredElon Musk to Trigger Next AI Wave on November 11th?Jeff Brown picked Nvidia in 2016, before shares surged 37,800 percent. Now he's identified another AI company ...Brownstone Research | SponsoredBezos… DOOMEDA single FCC filing hints Elon Musk is planning his biggest project yet - bigger than Tesla, SpaceX, and X com...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Tiziana Life Sciences PLC Please log in to your account or sign up in order to add this asset to your watchlist. Share Tiziana Life Sciences With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
